Highlights of our research include:

Optimization of microarray design, probe signal interpretation
Advanced models and tools for expression profiling
State-of-the-art applications and integrated analyses

Lab page @ http://bioinf.boku.ac.at/

Initial customers for the HiSeq X Ten System, which will ship in Q1 2014, include Macrogen, based in Seoul, South Korea and its CLIA laboratory in Rockville, Maryland, the Broad Institute in Cambridge, Massachusetts, and the Garvan Institute of Medical Research in Sydney, Australia.

“For the first time, it looks like it will be possible to deliver the $1,000 genome, which is tremendously exciting,” said Eric Lander, founding director of the Broad Institute and a professor of biology at MIT. “The HiSeq X Ten should give us the ability to analyze complete genomic information from huge sample populations. Over the next few years, we have an opportunity to learn as much about the genetics of human disease as we have learned in the history of medicine.”

“The HiSeq X Ten is an ideal platform for scientists and institutions focused on the discovery of genotypic variation to enable a deeper understanding of human biology and genetic disease,” Illumina stated. “It can sequence tens of thousands of samples annually with high-quality, high-coverage sequencing, delivering a comprehensive catalog of human variation within and outside coding regions.”

HiSeq X Ten utilizes a number of advanced design features to generate massive throughput. Patterned flow cells, which contain billions of nanowells at fixed locations, combined with a new clustering chemistry deliver a significant increase in data density (6 billion clusters per run). Using state-of-the art optics and faster chemistry, HiSeq X Ten can process sequencing flow cells more quickly than ever before — generating a 10x increase in daily throughput when compared to current HiSeq 2500 performance.

The HiSeq X Ten is sold as a set of 10 or more ultra-high throughput sequencing systems, each generating up to 1.8 terabases (Tb) of sequencing data in less than three days or up to 600 gigabases (Gb) per day, per system, providing the throughput to sequence tens of thousands of high-quality, high-coverage genomes per year. Illumina says the $1,000 includes typical instrument depreciation, DNA extraction, library preparation, and estimated labor.

The C-DAC will launch Param Bio Blaze, a supercomputing facility, to address the challenges in bioinformatics on Tuesday at a three-day symposium, titled: 'Accelerating biology: Computing life'. The supercomputing facility will be inaugurated on Tuesday by Ramakrishna Ramaswamy, vice-chancellor, Central University of Hyderabad at the Yashada. The new C-DAC's facility will have a capacity of 10 teraflop and will be able to analyse human cells and its functions.

Param Bio Blaze will help have a larger storage space and better computing facility for the bioinformatics sector. The facility will help capture the movement of molecules and also interaction between two molecules and the effects.

Applications of Param BioBlaze

- Collaboration with National Centre for Cell Science for research on Malaria and understanding how the disease spreads

- Collaborative work with Tata Memorial hospital on breast cancer and find out the difference between normal tissues and tissues from breast cancer patients

- Designing anti-cancer molecules, a collaborative research with the University of Pune

Reference:

Times of India

Image:datacenterjournal.com

Current computational interests:

Systematic analysis of genetic epistasis to identify redundant or compensatory systems and to reveal order of action in genetic pathways.
Using knockout, knockdown, or overexpression, or other perturbation experiments in combinations of genes in S. cerevisiae, C. elegans or mouse.
Using genome-scale genotyping of natural polymorphisms in S. cerevisiae and human populations.
Alternative splicing and its relationship to protein interaction networks.
Integrating large-scale studies including phenotype, genetic epistasis, protein-protein and transcription-regulatory interactions and sequence patterns to quantitatively assign function to genes and guide experimentation.

More at http://llama.mshri.on.ca/index.html

Welcome to phylobabble.org, a discussion forum for phylogenetic theory and applications. The primary goal of this forum is to discuss best practice and new developments in phylogenetics. Although we do have a Troubleshooting category for getting feedback on analyses, this is not a help site for running phylogenetics programs.

A great place to chat about phylogenetics for researchers and the broader community of students and science-interested citizens. 

Address of the bookmark: http://phylobabble.org/

The ongoing 2014 West Africa Ebola outbreak is considered to be the largest and longest outbreak ever recorded of Ebola, killing at least 932 people and infecting more than 1,700 till date since March in Sierra Leone, Guinea, Nigeria and Liberia.

Hence, the World Health Organisation (WHO) on 8 August, 2014 declared the killer Ebola epidemic ravaging parts of West Africa an international health emergency.

Causes

EVD is caused by infection with a virus of the family Filoviridae, genus Ebolavirus. While there are five identified sub-species of Ebolavirus, four viruses cause disease in humans. They are Bundibugyo virus (BDBV), Ebola virus (EBOV), Sudan virus (SUDV), Taï Forest virus (TAFV).

The fifth virus, Reston virus (RESTV), is not considered to be disease-causing in humans.

According to WHO, EVD first appeared in 1976 in two simultaneous outbreaks, in Nzara, Sudan, and in Yambuku, Democratic Republic of Congo. The latter was in a village situated near the Ebola River from which the disease takes its name.

How does it spread?

It is still unclear how Ebola spreads. However, it is believed that the first pateint becomes infected through contact with an infected animal's body fluids.

Human-to-human transmission can occur through direct contact with blood, organs or other body fluids of infected people or exposure to objects such as needles and syringes that have been contaminated with infected secretions.

Ebola can also be transmitted from men who have recovered from the disease through semen as it is infectious for up to 7 weeks.

Infected dead bodies can spread Ebola as they are still infectious. So mourners who have direct contact with the body of deceased person can also get the disease.

Who is most at risk?

Health-care workers who do not wear appropriate protective clothing and family members who are in close contact with infected people or deceased patients.

Signs and symptoms:

Symptoms may occur between 2 and 21 days after contracting the infection. Common signs of Ebola include:

Fever

Headache

Muscle, abdominal and joint pain

Sore throat

Weakness

Diarrhea

Vomit or cough up blood

Chest pain

Difficulty in breathing and swallowing

Rash

Hiccups

Bleeding inside and outside the body

Prevention

Currently there is no vaccine available for humans. But the infection can be controlled through the use of recommended protective measures such as:

Avoid contacting infected blood or secretions, including from those who are dead .

Using standard precautions for all patients in the healthcare setting.

Sterilizing equipment, and wearing protective clothing including masks, gloves, gowns and goggles.

Washing your hands with soaps or detergents.

Disinfecting your surroundings.

Isolate people who have Ebola symptoms.

Culling of infected animals, with close supervision of burial or incineration of carcasses.

Yet, not travelling to the areas or countries where the virus is found is the best way to avoid Ebola.

Please visit our site at www.arraygen.com